Results 171 to 180 of about 19,999 (193)

Avatrombopag in thrombopoietin receptor agonist-naïve patients with immune thrombocytopenia: real-world treatment patterns and clinical outcomes from the REAL-AVA 3.0 study. [PDF]

Res Pract Thromb Haemost
Panch S, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Jiang D.   +8 more
europepmc   +1 more source

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. [PDF]

Br J Haematol
Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H.   +8 more
europepmc   +1 more source

Subacute Stent Thrombosis Associated With Prasugrel Refractoriness in a Patient With Chronic ITP. [PDF]

JACC Case Rep
Takeo M, Okabe H, Hidaka K, Naka Y, Setoyama K, Kataoka M.   +5 more
europepmc   +1 more source

Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists

FEBS Journal, 2007
Thrombopoietin is the primary regulator of platelet production. We exploited two naturally occurring miniproteins of the inhibitor cystine knot family as stable and rigid scaffolds for the incorporation of peptide sequences that have been shown to act as
Matthias Ballmaier, Harald Kolmar, Alexander Wentzel   +2 more
exaly   +2 more sources

Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?

Seminars in Hematology, 2016
In 2008, new drugs that mimic the effects of thrombopoietin became available for the treatment of primary immune thrombocytopenia, eg, romiplostim and eltrombopag.
Alexandra Schifferli, Thomas Kühne
exaly   +2 more sources

Diagnosis and Management of Immune Thrombocytopenia in the Era of Thrombopoietin Mimetics

Hematology, 2011
The recognition of that patients with Immune Thrombocytopenia (ITP) have functional thrombopoietin deficiency and decreased platelet production due to immune-mediated megakaryocytic injury has challenged the traditional view of this disease as ...
Howard A Liebman, Vinod Pullarkat
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Structure of the thrombopoietin-MPL receptor complex is a blueprint for biasing hematopoiesis

Cell, 2023
Kenan Garcia, Naotaka Tsutsumi
exaly  

The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag

Blood Reviews, 2022
David John Kuter
exaly  

Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia

Therapeutic Advances in Hematology, 2019
Hanny Al-Samkari, David John Kuter
exaly